Introduction

In high-income countries a market-driven pharmaceutical industry does not always sufficiently respond to the needs of particular patient groups, such as women and children. In addition, across the world, it excludes those population groups who represent commercially non-viable medical needs, despite the fact that their illnesses account for a significantly large proportion of the global health burden.
The commercial power and influence of the pharmaceutical industry in national and global healthcare policy has thrown up a visible divide between trade competitiveness and public health. Increasingly public health appears to be sacrificed in the race between regions for trade superiority. Health care systems are under enormous strain, and costs continue to spiral, without clear signs of benefits for the public. Yet it is the public that pays for innovation in health through a number of mechanisms such as taxes, corporate tax breaks and credits, health insurance schemes, and through legal frameworks such as patents.

As need-driven health research is becoming increasingly important: WHO is developing a global strategy and plan of action, and HAI members all over the world are actively working on a future scenario: Where the market fails, new approaches to pharmaceutical R&D are called for.


EU-CAN Alliance on Access to Medicines

HAI Europe and HAI Latin America have formed an alliance between European and Latin American civil society to monitor and lobby negotiations on Association Agreements between the EU and the countries of the Andean region. Rigid Intellectual Property Rights provisions demanded by the EU are likely to have a negative effect on Access to Essential Medicines.

HAI Europe coordinates civil society efforts in Europe and raises awareness at the European Parliament, the Commission and the Council about the potentially harmful impact of the Association Agreements on public health in the Andean countries.

HAI Latin America will bring together civil society organisations in the region, lobby their respective national governments and provide the evidence base to support the HAI Europe advocacy campaign.

2 December 2008 Policy Brief - The EU-CAN Association Agreement, Access to Medicines in jeopardy!

December 2008 Factsheet - EU-CAN Association Agreements Negotiations – This factsheet was developed in cooperation with Evert Vermeer Stichting in the context of their European Union Coherence programme


See Literature Review - Media


Read more